Internal Medicine, Medical Oncology · New York, NY
NPI
1336438258
Since 2011
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
160 E 34th St
New York, NY, 10016
Phone (212) 731-6366
Groups this clinician bills Medicare through
Medicare paid, 2024
$83K
938 services
Medicare patients, 2024
335
Average age 77
Drug cost, 2024
$5.3M
1,219 prescriptions
Company payments, 2025
$4,531
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Wise was code 99214 (office e&m - established), 555 times for 260 patients. In total David R Wise billed 938 services in 17 codes, and Medicare paid $83K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 555 | 260 | $81.74 | $45K |
| 99215 Office E&M - Established | Office | 160 | 75 | $112.50 | $18K |
| 99205 Office E&M - New | Office | 73 | 73 | $156.37 | $11K |
| 99442 Telephone Services | Office | 44 | 33 | $57.01 | $2,508 |
| 99441 Telephone Services | Office | 34 | 27 | $27.46 | $934 |
| 99443 Telephone Services | Office | 16 | 14 | $81.60 | $1,306 |
| 99213 Office E&M - Established | Office | 12 | 12 | $67.26 | $807 |
By year: 2022 $66K for 909 services; 2023 $79K for 895 services; 2024 $83K for 938 services.
Medicare prescription drug claims, 2024
In 2024, the drug David R Wise prescribed most often to Medicare patients was Prednisone, with 210 prescriptions and refills. In total David R Wise wrote 1,219 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 210 | 228 | 41 | $803 |
| Abiraterone Acetate Generic | 197 | 212 | 29 | $445K |
| Nubeqa Darolutamide | 151 | 155 | 31 | $1.9M |
| Orgovyx Relugolix | 145 | 148 | 30 | $390K |
| Xtandi Enzalutamide | 117 | 117 | 24 | $1.6M |
| Bicalutamide Generic | 57 | 69 | 37 | $1,610 |
| Lynparza Olaparib | 43 | 43 | Under 11 | $488K |
| Dexamethasone Generic | 38 | 43 | 14 | $197 |
| Tamsulosin Hcl Generic | 27 | 45 | 11 | $275 |
| Oxycodone Hcl Generic | 25 | 27 | Under 11 | $440 |
| Gabapentin Generic | 23 | 29 | 12 | $129 |
| Cabometyx Cabozantinib S-Malate | 14 | 14 | Under 11 | $195K |
| Tramadol Hcl Generic | 14 | 14 | 11 | $48.61 |
| Talzenna Talazoparib Tosylate | 14 | 14 | Under 11 | $256K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 12 | 22 | Under 11 | $64.28 |
Brand drugs: 508 claims; generic drugs: 711 claims; opioid claims: 58.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David R Wise $4,531 ($4,216 in general payments such as food, travel and fees and $315 for research) from 10 companies. The largest payer was Pfizer Inc. with $2,360.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.